Cite
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme.
MLA
Su Min Chang, et al. “Efficacy and Safety of Angiotensin Receptor Blockade Are Not Modified by Aspirin in Patients with Chronic Heart Failure: A Cohort Study from the Candesartan in Heart Failure – Assessment of Reduction in Mortality and Morbidity (CHARM) Programme.” European Journal of Heart Failure, vol. 12, no. 7, July 2010, pp. 738–45. EBSCOhost, https://doi.org/10.1093/eurjhf/hfq065.
APA
Su Min Chang, Granger, C. B., Johansson, P. A., Kosolcharoen, P., McMurray, J. J. V., Michelson, E. L., Murray, D. R., Olofsson, B., Pfeffer, M. A., Solomon, S. D., Swedberg, K., Yusuf, S., & Dunlap, M. E. (2010). Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure, 12(7), 738–745. https://doi.org/10.1093/eurjhf/hfq065
Chicago
Su Min Chang, Christopher B. Granger, Peter A. Johansson, Peter Kosolcharoen, John J. V. McMurray, Eric L. Michelson, David R. Murray, et al. 2010. “Efficacy and Safety of Angiotensin Receptor Blockade Are Not Modified by Aspirin in Patients with Chronic Heart Failure: A Cohort Study from the Candesartan in Heart Failure – Assessment of Reduction in Mortality and Morbidity (CHARM) Programme.” European Journal of Heart Failure 12 (7): 738–45. doi:10.1093/eurjhf/hfq065.